Unicycive Therapeutics Executes Reverse Stock Split

Unicycive Therapeutics ( (UNCY) ) has issued an update.

On June 9, 2025, Unicycive Therapeutics‘ stockholders approved a reverse stock split, which was executed at a 1-for-10 ratio effective June 18, 2025. This move, aimed at regaining compliance with Nasdaq’s $1.00 minimum bid price requirement, reduced the number of outstanding shares from approximately 126.4 million to 12.6 million, without affecting stockholders’ percentage ownership or voting power.

The most recent analyst rating on (UNCY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Unicycive Therapeutics stock, see the UNCY Stock Forecast page.

Spark’s Take on UNCY Stock

According to Spark, TipRanks’ AI Analyst, UNCY is a Underperform.

Unicycive Therapeutics has significant financial challenges, including ongoing net losses and a reliance on debt for financing, which weigh heavily on its stock score. The technical analysis reveals a bearish trend, as the stock is trading below major moving averages. Valuation metrics further dampen the attractiveness of the stock due to negative profitability indicators. Without earnings call insights or recent corporate events to improve prospects, the overall score reflects these financial and technical weaknesses.

To see Spark’s full report on UNCY stock, click here.

More about Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company focused on developing novel treatments for kidney diseases. Their lead investigational treatment is oxylanthanum carbonate, a phosphate binding agent under FDA review for hyperphosphatemia in dialysis patients. Another investigational treatment, UNI-494, targets conditions related to acute kidney injury and has orphan drug designation for preventing Delayed Graft Function in kidney transplant patients.

Average Trading Volume: 3,060,430

Technical Sentiment Signal: Buy

Current Market Cap: $84.38M

For detailed information about UNCY stock, go to TipRanks’ Stock Analysis page.